Beatrice Rendenbach‐Mueller

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 130 citations · Full text

Clinical Trials, Progressive Supranuclear Palsy, Placebo-controlled Trial +7

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Hana Florian, Deli Wang, Steven E. Arnold et al. · Brain · 2023 · 119 citations · Full text

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence

Megan L. Ryan, Daniel E. Falk, Joanne B. Fertig et al. · Neuropsychopharmacology · 2016 · 68 citations · Full text

Substance Abuse, Alcohol Misuse, Substance Use +11

A Double-Blind, Randomized, Placebo-Controlled Study of the Dopamine D3 Receptor Antagonist ABT-925 in Patients With Acute Schizophrenia

Laura Redden, Beatrice Rendenbach‐Mueller, Walid Abi‐Saab et al. · Journal of Clinical Psychopharmacology · 2011 · 39 citations

Dopamine D₃ Receptor, Acute Schizophrenia, Psychiatry +15

[O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER's DISEASE

Kumar Budur, Tim West, Joel B. Braunstein et al. · Alzheimer s & Dementia · 2017 · 11 citations

Clinical Neurology, Neurochemical Biomarkers, Pharmacotherapy +16